Date: 2014-06-06
Type of information: Grant
Company: Trianta Immunotherapies, a Medigene subsidiary (Germany)
Investors: Federal Ministry of Education and Research (BMBF) (Germany)
Amount: €380 000
Funding type: grant
Planned used: Trianta\'s anti-TCR monoclonal antibodies platform serves to generate monoclonal antibodies which recognise different T cells based on their T cell receptors. These T cell-specific antibodies are intended to remove unwanted cells from the body in order to treat T cell-induced diseases such as T cell leukaemia or various autoimmune diseases. This platform has helped to produce and characterise monoclonal antibodies which are able to distinguish between different T cell receptors. Proof of technology was established in preclinical experiments. The sponsored project intends to provide evidence of the elimination of pathogenic T cells in T-cell leukemia and autoimmune diseases, applying in-vivo and in-vitro methods with T-cell receptor-specific monoclonal antibodies.
Others: * On June 6, 2014, Medigene announced that its subsidiary Trianta Immunotherapies GmbH will receive public funding for the development of its immunotherapy platform TABs (T-cell-specific AntiBodies) for the treatment of various types of cancer and autoimmune diseases. The grant is awarded by the Federal Ministry of Education and Research, (Bundesministerium für Bildung und Forschung = BMBF) within the scope of the \"m4 - Personalized Medicine and Targeted Therapies: a new Dimension of Drug Development\" Munich Leading-Edge Cluster initiative. The sponsored project totalling €380 k is financed by Medigene (60%) as well as the BMBF grant (40%).
Therapeutic area: Cancer - Oncology - Autoimmune diseases
